112P Patients’ knowledge about ductal carcinoma in situ
Ellen G. Engelhardt(The Netherlands Cancer Institute), Eveline M. A. Bleiker(Leiden University Medical Center), E. Verschuur-van der Voort(Borstkankervereniging Nederland), C. Sondermeijer(The Netherlands Cancer Institute), Miranda A. Gerritsma(The Netherlands Cancer Institute), Frederieke van Duijnhoven(The Netherlands Cancer Institute), Marja van Oirsouw(Borstkankervereniging Nederland), Renée Schmitz(The Netherlands Cancer Institute), Valesca P. Retèl(The Netherlands Cancer Institute), Jelle Wesseling(Leiden University Medical Center)
Cited by 0
Related Papers
Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype
|Journal of Clinical Oncology|2011|306
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
|The Lancet Oncology|2007|278
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
|Breast Cancer Research and Treatment|2009|256
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
|British Journal of Cancer|2013|241